Radotinib
- Generic Name
- Radotinib
- Drug Type
- Small Molecule
- Chemical Formula
- C27H21F3N8O
- CAS Number
- 926037-48-1
- Unique Ingredient Identifier
- I284LJY110
- Background
Radotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
- Indication
Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath